DE602004008773T2 - 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten - Google Patents
2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten Download PDFInfo
- Publication number
- DE602004008773T2 DE602004008773T2 DE602004008773T DE602004008773T DE602004008773T2 DE 602004008773 T2 DE602004008773 T2 DE 602004008773T2 DE 602004008773 T DE602004008773 T DE 602004008773T DE 602004008773 T DE602004008773 T DE 602004008773T DE 602004008773 T2 DE602004008773 T2 DE 602004008773T2
- Authority
- DE
- Germany
- Prior art keywords
- amino
- propyl
- phenyl
- aminopyridin
- hydroxyethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*c1c(CC(C)N)c(*)c(*)c(*)c1* Chemical compound C*c1c(CC(C)N)c(*)c(*)c(*)c1* 0.000 description 10
- LYBWKEZEFCVJRY-UHFFFAOYSA-N CC(C)(Cc1cccc(Br)c1)NC(CCl)=O Chemical compound CC(C)(Cc1cccc(Br)c1)NC(CCl)=O LYBWKEZEFCVJRY-UHFFFAOYSA-N 0.000 description 1
- FXFLLVUKVBSPDM-UHFFFAOYSA-N CC(C)(c(cc1)ccc1N=O)[Zn] Chemical compound CC(C)(c(cc1)ccc1N=O)[Zn] FXFLLVUKVBSPDM-UHFFFAOYSA-N 0.000 description 1
- CCUFJSRTMDUHLG-UHFFFAOYSA-N CC(Cc1cc(CC(OC)=O)ccc1)=O Chemical compound CC(Cc1cc(CC(OC)=O)ccc1)=O CCUFJSRTMDUHLG-UHFFFAOYSA-N 0.000 description 1
- DPCGNWYKERNENU-UHFFFAOYSA-N CCOC(Cc1ccc(CC(C)(C)N(C(c2ccccc22)O)C2=O)cc1)O Chemical compound CCOC(Cc1ccc(CC(C)(C)N(C(c2ccccc22)O)C2=O)cc1)O DPCGNWYKERNENU-UHFFFAOYSA-N 0.000 description 1
- CILRUTIVKYGOJF-RPLLCQBOSA-N C[C@@](Cc1cccc(CC(NC(C2)Cc3c2cccc3)=O)c1)(NC[C@@H](c1ccc(N)nc1)O)O Chemical compound C[C@@](Cc1cccc(CC(NC(C2)Cc3c2cccc3)=O)c1)(NC[C@@H](c1ccc(N)nc1)O)O CILRUTIVKYGOJF-RPLLCQBOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0312832.9A GB0312832D0 (en) | 2003-06-04 | 2003-06-04 | 2-amino-pyridine derivatives useful for the treatment of diseases |
| GB0312832 | 2003-06-04 | ||
| PCT/IB2004/001850 WO2004108676A1 (en) | 2003-06-04 | 2004-06-01 | 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamine derivatives as beta 2-adrenoceptors agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004008773D1 DE602004008773D1 (de) | 2007-10-18 |
| DE602004008773T2 true DE602004008773T2 (de) | 2008-01-10 |
Family
ID=9959308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004008773T Expired - Fee Related DE602004008773T2 (de) | 2003-06-04 | 2004-06-01 | 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1633715B1 (https=) |
| JP (1) | JP2006526613A (https=) |
| AR (1) | AR044475A1 (https=) |
| AT (1) | ATE372321T1 (https=) |
| BR (1) | BRPI0410946A (https=) |
| CA (1) | CA2527788A1 (https=) |
| CL (1) | CL2004001366A1 (https=) |
| DE (1) | DE602004008773T2 (https=) |
| ES (1) | ES2291882T3 (https=) |
| GB (1) | GB0312832D0 (https=) |
| GT (1) | GT200400116A (https=) |
| MX (1) | MXPA05012840A (https=) |
| NL (1) | NL1026329C2 (https=) |
| PA (1) | PA8604301A1 (https=) |
| PE (1) | PE20050628A1 (https=) |
| TW (1) | TW200524603A (https=) |
| UY (1) | UY28339A1 (https=) |
| WO (1) | WO2004108676A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| BRPI0515482A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seus usos como agentes terapêuticos |
| AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| CN101084211A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| CA2618646A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| JP2009504624A (ja) | 2005-08-08 | 2009-02-05 | アージェンタ ディスカバリー リミテッド | ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用 |
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| PT2322525E (pt) | 2006-04-21 | 2013-12-26 | Novartis Ag | Derivados de purina para utilização como agonistas do recetor de adenosina a2a |
| PT2035004E (pt) * | 2006-06-09 | 2012-11-21 | Parion Sciences Inc | Bloqueadores dos canais de sódio de pirazinoilguanidona substituída com fenilo que possuem actividade agonista beta |
| EP2535330A3 (en) | 2006-10-23 | 2012-12-26 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
| CN101687851B (zh) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | 有机化合物 |
| CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
| AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
| US8481569B2 (en) | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
| CA2727196A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| DE102008049675A1 (de) | 2008-09-30 | 2010-04-01 | Markus Dr. Heinrich | Verfahren zur Herstellung von 3-Aminobiphenylen |
| MX2011007036A (es) | 2008-12-30 | 2011-07-20 | Pulmagen Therapeutics Inflammation Ltd | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios. |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
| AU2020338971B2 (en) | 2019-08-28 | 2023-11-23 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| US5977124A (en) * | 1995-05-10 | 1999-11-02 | Pfizer Inc. | β-adrenergic agonists |
| DE60015036T2 (de) * | 1999-07-23 | 2006-03-02 | Pfizer Products Inc., Groton | Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| ES2302938T3 (es) * | 2002-10-11 | 2008-08-01 | Pfizer Inc. | Derivados de indol como agonistas beta-2. |
-
2003
- 2003-06-04 GB GBGB0312832.9A patent/GB0312832D0/en not_active Ceased
-
2004
- 2004-06-01 DE DE602004008773T patent/DE602004008773T2/de not_active Expired - Fee Related
- 2004-06-01 CA CA002527788A patent/CA2527788A1/en not_active Abandoned
- 2004-06-01 BR BRPI0410946-5A patent/BRPI0410946A/pt not_active IP Right Cessation
- 2004-06-01 MX MXPA05012840A patent/MXPA05012840A/es unknown
- 2004-06-01 WO PCT/IB2004/001850 patent/WO2004108676A1/en not_active Ceased
- 2004-06-01 JP JP2006508431A patent/JP2006526613A/ja not_active Withdrawn
- 2004-06-01 EP EP04735621A patent/EP1633715B1/en not_active Expired - Lifetime
- 2004-06-01 AT AT04735621T patent/ATE372321T1/de not_active IP Right Cessation
- 2004-06-01 ES ES04735621T patent/ES2291882T3/es not_active Expired - Lifetime
- 2004-06-01 PE PE2004000553A patent/PE20050628A1/es not_active Application Discontinuation
- 2004-06-02 UY UY28339A patent/UY28339A1/es not_active Application Discontinuation
- 2004-06-03 CL CL200401366A patent/CL2004001366A1/es unknown
- 2004-06-03 TW TW093115990A patent/TW200524603A/zh unknown
- 2004-06-03 AR ARP040101904A patent/AR044475A1/es unknown
- 2004-06-03 GT GT200400116A patent/GT200400116A/es unknown
- 2004-06-03 NL NL1026329A patent/NL1026329C2/nl not_active IP Right Cessation
- 2004-06-03 PA PA20048604301A patent/PA8604301A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0410946A (pt) | 2006-06-27 |
| AR044475A1 (es) | 2005-09-14 |
| EP1633715B1 (en) | 2007-09-05 |
| CA2527788A1 (en) | 2004-12-16 |
| WO2004108676A1 (en) | 2004-12-16 |
| ES2291882T3 (es) | 2008-03-01 |
| GT200400116A (es) | 2005-03-03 |
| MXPA05012840A (es) | 2006-02-13 |
| UY28339A1 (es) | 2005-01-31 |
| ATE372321T1 (de) | 2007-09-15 |
| DE602004008773D1 (de) | 2007-10-18 |
| JP2006526613A (ja) | 2006-11-24 |
| CL2004001366A1 (es) | 2005-05-06 |
| GB0312832D0 (en) | 2003-07-09 |
| EP1633715A1 (en) | 2006-03-15 |
| NL1026329C2 (nl) | 2005-07-26 |
| TW200524603A (en) | 2005-08-01 |
| PA8604301A1 (es) | 2004-12-16 |
| NL1026329A1 (nl) | 2004-12-07 |
| PE20050628A1 (es) | 2005-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004008773T2 (de) | 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten | |
| DE602004011513T2 (de) | 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten | |
| DE602005001929T2 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| EP1730103B1 (en) | Formamide derivatives useful as adrenoceptor | |
| DE60320439T2 (de) | INDOLDERIVATE ALS ß2-AGONISTEN | |
| DE602005002930T2 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| EP1624868B9 (en) | "(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)- propyl]phenyl derivatives as beta2 agonists | |
| US20040229904A1 (en) | Compounds useful for the treatment of diseases | |
| WO2005092861A1 (en) | Quinolinone derivatives pharmaceutical compositions containing them and their use | |
| NL1028599C2 (nl) | Verbindingen voor de behandeling van ziekten. | |
| WO2005092841A1 (en) | Compounds having beta-agonist activity | |
| JP2007529499A (ja) | β２受容体アゴニストとしてのフェニルアミノエタノール誘導体 | |
| EP1730141B1 (en) | Compounds for the treatment of diseases | |
| EP1577291A1 (en) | Phenylethanolamine derivatives as beta-2 agonists | |
| US7375100B2 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
| JP4054366B2 (ja) | 疾患の治療のために有用な化合物 | |
| EP1574501A1 (en) | Quinolinone derivatives, pharmaceutical compositions containing them and their use | |
| JP4819770B2 (ja) | アドレナリン受容体として有用なホルムアミド誘導体 | |
| HK1096379B (en) | Sulfonamide derivatives for the treatment of diseases | |
| HK1096379A1 (zh) | 用於治疗疾病的磺酰胺衍生物 | |
| KR20070026425A (ko) | 질환 치료용 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |